Leisha Emens, MD, Oncology, Pittsburgh, PA, UPMC Presbyterian

LeishaAnnEmensMDPhD

Oncology Pittsburgh, PA

Hematologic Oncology

Professor of Medicine, University of Pittsburgh, UPMC Hillman Cancer Center; Co-Leader, Hillman Cancer Immunology and Immunotherapy Program; Director, Translational Immunotherapy for the Women's Cancer Research Center, Magee Women's Hospital

Overview of Dr. Emens

Dr. Leisha Emens is an oncologist in Pittsburgh, PA and is affiliated with multiple hospitals in the area, including UPMC Presbyterian, UPMC Magee-Womens Hospital, and James E. Van Zandt Veterans Affairs Medical Center. She received her medical degree from Baylor College of Medicine and has been in practice 22 years. Dr. Emens accepts several types of health insurance, listed below. She is one of 82 doctors at UPMC Magee-Womens Hospital and one of 170 doctors at UPMC Presbyterian who specialize in Oncology.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFELLOWSHIP
  • University of Texas Southwestern Medical School
    University of Texas Southwestern Medical SchoolRESIDENCY
  • Baylor College of Medicine
    Baylor College of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2018 - 2020
  • MD State Medical License
    MD State Medical License 1998 - 2022
  • TX State Medical License
    TX State Medical License 1997 - 1999
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2012-2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
  • America's Top Doctors for Cancer Castle Connolly, 2011-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer 
    International Society for Biological Therapy of Cancer (iSBTc)/ Society for Immunotherapy of Cancer, - 10/24/2012
  • Breast and Gynecologic Cancers. Integrating Immunotherapy Into Clinical Practice: Changes Over the Past Year (Part 1) 
    2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018

Press Mentions

  • Silverback Therapeutics to Present Data on Two Programs at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting
    Silverback Therapeutics to Present Data on Two Programs at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual MeetingNovember 10, 2020 12:52
  • Society for Immunotherapy of Cancer Announces Officers, at-Large Directors
    Society for Immunotherapy of Cancer Announces Officers, at-Large DirectorsJuly 13, 2020 09:28
  • Atezolizumab Added to T-dM1 Improves OS and PFS in HER2+ Breast Cancer
    Atezolizumab Added to T-dM1 Improves OS and PFS in HER2+ Breast CancerNovember 24, 2019 04:55
  • Join now to see all

Grant Support

  • Chemoimmunotherapy For Breast Cancer TreatmentNational Cancer Institute2003–2006

Professional Memberships

Hospital Affiliations

Insurance Accepted

  • AvMed Health Open Access
    BCBS Blue Card PPO
    CareFirst BCBS Maryland POS
    CareFirst BlueChoice Advantage
    CareFirst BlueChoice Network POS
    CareFirst BluePreferred PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    First Health PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment